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Abstract 
The serine/threonine kinase MAP4K4 is a member of the Ste20p (sterile 20 protein) family. MAP4K4 was initially discov-
ered in 1995 as a key kinase in the mating pathway in Saccharomyces cerevisiae and was later found to be involved 
in many aspects of cell functions and many biological and pathological processes. The role of MAP4K4 in immunity, 
inflammation, metabolic and cardiovascular disease has been recognized. Information regarding MAP4K4 in cancers is 
extremely limited, but increasing evidence suggests that MAP4K4 also plays an important role in cancer and MAP4K4 
may represent a novel actionable cancer therapeutic target. This review summarizes our current understanding of 
MAP4K4 regulation and MAP4K4 in cancer. MAP4K4-specific inhibitors have been recently developed. We hope that 
this review article would advocate more basic and preclinical research on MAP4K4 in cancer, which could ultimately 
provide biological and mechanistic justifications for preclinical and clinical test of MAP4K4 inhibitor in cancer patients.
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Background
MAP4K4, also known as HGK (hematopoietic progenitor 
kinase/germinal center kinase-like kinase) or NIK (Nck 
interacting kinase, the mouse ortholog) is a serine/threo-
nine (S/T) kinase that belongs to the mammalian family 
of Ste20 protein kinases due to their shared homology 
to the budding yeast kinase Ste20p [1]. Ste20 family con-
sists of more than 30 members that can be divided into 
two subgroups based on the location of their catalytic 
domains (N-terminals vs. C-terminals): the p21-activated 
kinases (PAKs, C-terminals) and the germinal center-like 
kinases (GCKs, N-terminals) [1]. Based on the wide vari-
ety of structure in the noncatalytic regions of the GCKS, 
these kinases are further divided into eight subfamilies 
[2]. MAP4K4 is one of four members of the mammalian 
GCK-IV subfamily [1, 3–6].
MAP4K4 contains ~1200 amino acids with a molecu-
lar mass of ~140 KDa [7, 8]. The orthologues of MAP4K4 
among different species share similar molecular struc-
ture. Human MAP4K4 gene is located at 2q11.2 in 
human chrome [1]. MAP4K4 is expressed in all tissue 
types examined [7] but appears to express at relatively 
higher levels in the brain and testis [9]. Five alternatively 
spliced transcript variants encoding different isoforms of 
human MAP4K4 can be found in NCBI database. These 
splice variants contain identical kinase domain at the 
N-terminus and alternative splicing appears to mainly 
affect the intermediate regions of MAP4K4. Mouse 
MAP4K4 (NIK) has two proline-rich motifs in its inter-
mediate domain through which NIK binds with SH3 (the 
SRC homology 3) domain of NCK adapter protein [8, 10]. 
The long version of MAP4K4 and MAP4K4 cloned from 
tumor cells, but not the short version of MAP4K4, also 
contain proline-rich regions [9]. Although the biological 
significance of all MAP4K4 isoforms remains to be deter-
mined, it is reasonable to speculate that variation in the 
middle domain could affect MAP4K4 interaction with 
other factors, resulting in different biochemical and phys-
iological consequences. While multiple isoforms can be 
present in the same cell, the relative abundance of each 
isoform in a given cell appears to be different in a cell-
type or tissue-type specific manner [9]. For instance, the 
shorter version of MAP4K4 is predominately expressed 
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in human brain, liver, skeletal muscle and placenta, the 
longer version is more abundant in the brain [9]. The 
tissue-specific expression patterns of MAP4K4 isoforms 
could suggest that each isoform may have a distinct or 
tissue-specific function or the regulation of each isoform 
could be tissue- or cell type-specific.
As summarized in Table 1, the functional significance 
of MAP4K4 in biology has been firmly established based 
on genetic evidence from mouse models. Whole-body or 
endothelial-specific knockout of MAP4K4 is embryonic 
lethal due to impaired mesodermal and somite develop-
ment and decreased migration activity of endothelial 
cells respectively [11, 12]. Besides its essential role in 
embryonic development, MAP4K4 has also been impli-
cated in focal adhesion dynamics regulation [13], sys-
temic inflammation [14], lung inflammation [15], type 2 
diabetes [16, 17], atherosclerosis [18] and insulin sensi-
tivity [19]. For detailed information regarding MAP4K4 
in immunity/inflammation and metabolic/cardiovascular 
diseases, we refer the reader to two excellent reviews [20, 
21]. In this review, we will discuss current understand-
ing of MAP4K4 regulation and summarize evidence that 
implicates MAP4K4 in cancer.
Regulation of MAP4K4 kinase activity and gene expression
Despite different localizations of their catalytic domains 
(N-terminus vs. C-terminus), mammalian Ste20 kinases 
share similar features in the kinase domain [1]. In general, 
activation of most Ste20 family kinases appears to require 
phosphorylation of a primary site in the activation seg-
ment of the kinase [1]. It is believed that phosphoryla-
tion stabilizes the activation segment in a conformation 
suitable for substrate binding and the unphosphorylated 
activation segment is largely unstructured [1]. Many 
Ste20 kinases also require phosphorylation of additional 
residues (secondary sites) by upstream kinases or from 
autophosphorylation for full activity [1]. In NIK, the 
mouse ortholog of MAP4K4, replacing aspartate (D) 
152 with asparagine (N) abolished the kinase activity of 
NIK [8]. But potential phosphorylation site required for 
full kinase activity of NIK has not been identified. In 
human Map4K4, as summarized in Fig. 1, several amino 
acid residues in the N-terminal kinase domain have been 
implicated in the regulation of MAP4K4 activity includ-
ing lysine 54 (K54), aspartate 153 (D153, correspond-
ing site of NIK D152), threonine 181 (T181), threonine 
187 (T187) and threonine 191 (T191) [9, 12, 13]. Result 
of in  vitro kinase assay using MAP4K4 mutant protein 
as enzyme and myelin basic protein (MBP) as substrate 
showed that mutation of T187 to E slightly increased the 
catalytic activity of MAP4K4 [9], suggesting that this is 
a potential phosphorylation site. Regarding T181, there 
is no in  vitro kinase assay result available showing that 
T181A (replacing threonine to alanine) mutation abol-
ishes MAP4K4 kinase activity, whereas T181D or T181E 
mutation increases or restores MAP4K4 activity. How-
ever, this mutant (T181E) was used in a recent study as a 
phosphor-mimetic mutant [12]. Mutation of T191 to glu-
tamate (E) or K54 to arginine (R), completely abrogated 
the kinase activity of MAP4K4, indicating that these two 
residues are required for MAP4K4 kinase activity. If T191 
is a phosphorylation site, the result suggests that phos-
phorylation of T191 has a negative impact on MAP4K4 
kinase activity. Phosphorylation of T181 and T187 or 
T191 has not been verified in  vivo. The biochemical 
and biological consequences of these phosphorylations 
remain to be determined. Identifying upstream kinases 
responsible for the phosphorylation will help to under-
stand how MAP4K4 is regulated in biological contests.
Taking the global phosphoproteomics approach and 
by comparing the corresponding SILAC (Stable Isotope 
Labeling by Amino acids in Cell) ratios of EGF (epidermal 
growth factor) stimulation and erlotinib (EGFR inhibitor) 
treatment in lung adenocarcinoma cells, a prior study 
identified two serine sites S648 and S708 in the middle 
domain of MAP4K4 as EGFR (epidermal growth fac-
tor receptor) signaling-dependent phosphorylation sites 
[22]. Serine 648 is conserved among the five MAP4K4 
isoforms mentioned above [7, 9], but serine 708 is miss-
ing in the corresponding position of the above isoforms, 
suggesting that there could be an unidentified isoform of 
MAP4K4 or it was simply due to incorrect matches [23]. 
Although phosphorylation of these sites need to be fur-
ther verified by mutation strategy and the biochemical 
Table 1 Summary of MAP4K4 knockout mouse models
Tissue/cell type Phenotype Ref.
Whole-body knockout Embryonic lethality [11]
Whole-body-inducible knockout Reduced plasma glucose levels and enhanced insulin sensitivity [19]
Skin conditional knockout Aberrant wound repair and epidermal cell migration defects [13]
T cell-specific knockout Systemic inflammation and type 2 diabetes [16]
Endothelial cell-specific knockout Embryonic lethality [12]
Endothelial cell-specific inducible knockout Protected from vascular inflammation and atherosclerosis [18]
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and biological consequences of these phosphorylations 
remain to be determined, the observation that in  vivo 
phosphorylation of these sites are regulated by EGFR 
signaling strongly support that the intermediate regions 
of MAP4K4 may also play an important role in the regu-
lation of MAP4K4 activity or function.
The C-terminal domain of MAP4K4 contains a citron-
homology domain (CNH) that appears to determine 
MAP4K4 association with other factors [9]. For instance, 
MAP4K4 interaction with Rap2 requires the entire CNH 
domain [24]. A human guanylate-binding protein (GBP) 
hGBP3, binds to the C-terminal regulatory domain of 
MAP4K4 [25]. Presumably through affecting protein–
protein interaction, the C-terminal domain of MAP4K4 
is believed to be involved in the regulation of MAP4K4 
activity. It has been shown that full activation of SAPK 
(Stress-activated protein kinases, also known as Jun 
amino-terminal kinases, JNK) by MAP4K4 requires both 
MAP4K4′s kinase activity and the C-terminal regulatory 
domain that mediates the association of MAP4K4 with 
MEKK1 (mitogen-activated protein kinase kinase kinase 
1) [8]. Although protein–protein interaction appears to 
determine MAP4K4 kinase activity, MAP4K4 interac-
tion with other proteins appears to not require its kinase 
activity. The results of coimmunoprecipitation assay 
have shown that wild-type MAP4K4 and kinase-inactive 
MAP4K4 (MAP4K4-K54R) exerted similar binding affin-
ity to transcription factor STAT3 (signal transducer and 
activator of transcription 3) in human embryonic kid-
ney (HEK) 293T cells [9]. Consistent with this, MAP4K4 
interacts with PYK2 (proline-rich tyrosine kinase 2) 
through the C-terminal portion of MAP4K4 and the asso-
ciation does not require catalytic activity of MAP4K4 [26].
Taken together, current evidence, as summarized 
above, strongly supports that the MAP4K4 kinase activ-
ity can be positively or negatively regulated by upstream 
kinases. The identities of the kinases remain largely 
unexplored. If multiple kinases are involved, it is highly 
likely that the selection within a repertoire of candidate 
kinases is context-dependent, depending on the cell type, 
the nature of the external stimuli, and the cell state. The 
biochemical and biological consequences of phospho-
rylation could also be context-dependent. In addition to 
negatively or positively regulating MAP4K4 kinase activ-
ity, phosphorylation may also determine MAP4K4 sub-
cellular localization and substrate-selection.
A recent study points to a possibility that in T cells of 
type 2 diabetes patients, mRNA level of MAP4K4 might 
be affected by enhanced methylation of CpG islands in its 
promoter region [17], suggesting epigenetic regulation 
could play a role in the regulation of MAP4K4 expression. 
Information regarding regulation of MAP4K4 by natural 
stimuli and transcription factors is extremely limited. To 
date, only two factors have been reported to be involved 
in modulating MAP4K4 expression: TNF-α and p53. 
TNF-α treatment, through TNF-α receptor 1 (TNFR1), 
increases MAP4K4 mRNA and protein expression in 
cultured adipocytes [27]. TNF-α can stimulate MAP4K4 
kinase activity in 293T cells [7] and in rat primary beta 
cells [28], which appears not to involve changes in 
MAP4K4 expression, suggesting mechanisms underly-
ing TNF-α regulation of MAP4K4 is context-dependent. 
Mouse MAP4K4/ NIK
Human MAP4K4/ HGK
(1288 aa)KD CNH 
(574-616)D20 D306
D152





Fig. 1 Schematic diagram of MAP4K4 structure. Both human and mouse MAP4K4 are composed of an N-terminal kinase domain and a C-terminal 
citron-homology domain. Mouse MAP4K4 contains proline-rich motifs. Sites involved in regulation of kinase activity and potential phosphorylation 
sites are indicated
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MAP4K4 gene contains a nearby p53 binding sites cluster 
downstream of the promoter and six potential p53 bind-
ing sites in the first intron, four of which are confirmed 
by chromatin immunoprecipitation (ChIP) experiments 
[9, 29]. Induction of p53 in p53-Saos-2 cells upregu-
lates MAP4K4 mRNA expression [29]. The physiologi-
cal relevance of TNF-α- and p53-mediated regulation of 
MAP4K4 expression still needs to be verified in biologi-
cal systems, given the fact that both TNF-α and p53 are 
broadly involved in human biology and diseases, these 
findings strongly support the notion that modulation of 
MAP4K4 expression could be an important mechanism 
of MAP4K4 regulation and could have important biologi-
cal and clinical significance.
MAP4K4 in cancer
Despite the fact that evidence from genetic studies using 
mouse model is still lacking, emerging evidence from 
preclinical and patient association studies strongly sug-
gests that MAP4K4 may play an important role in many 
types of cancer and could serve as a novel actionable 
target for cancer treatment. The first evidence suggest-
ing a role of MAP4K4 in cancer came from observations 
that MAP4K4 is highly expressed in 40 of the NCI-60 
human tumor cell lines and can modulate cellular trans-
formation, adhesion and invasion [9]. In this study, using 
MAP4K4 kinase-active (T187E) mutant or kinase-inac-
tive mutants (K54R or T191E) as a tool and rodent cells 
(NIH3T3 and RIE-1 cells) as cellular models, Wright 
et al. found that MAP4K4, in a kinase activity-dependent 
manner, positively regulate cell transformation and inva-
sion and negatively regulates cell spreading and adhesion, 
which provides the first clue suggesting that MAP4K4 
may promote tumor development and progression. As 
summarized in Table  2, since 2003, there is increasing 
evidence pointing to the possibility that MAP4K4 plays 
an important role in many types of tumors. Negative 
association between MAP4K4 expression and patient 
prognosis has been observed in several types of human 
cancer. Current evidence indicates that MAP4K4 can 
potentially serve as a negative prognostic indicator in 
patients with colorectal cancer (CRC) [30], hepatocel-
lular carcinoma (HCC) [31], pancreatic ductal adeno-
carcinoma (PDAC) [32], lung adenocarcinoma [33] and 
prostate cancer [34]. In cancer cells, in general, downreg-
ulation of MAP4K4 results in induction of apoptosis [31, 
35–38], cell cycle arrest [31, 37, 38] and inhibition of cell 
growth and proliferation [31, 37, 38], migration and inva-
sion [26, 37–40]. MAP4K4 may very likely participate in 
the regulation of other cellular functions and processes.
Little information exists regarding how MAP4K4 is 
involved in cancer. As shown in Fig.  2, knockdown of 
MAP4K4 affected the expression, activity or function 
of many factors that could act as a downstream effec-
tor or signaling mediator of MAP4K4. These factors can 
be grouped in several categories: kinase (MAPK/JNK) 
[31, 35, 39, 41]; transcription factor (NF-κB, STAT3 and 
HES1) [9, 31, 38, 40]; transmembrane receptor impor-
tant for cell–cell communication (Notch2 and Notch3) 
[38]; matrix metalloproteinases (MMP, MMP-2, MMP-9, 
MMP-7 and MMP13) [40, 42]; inhibitor of apoptosis nega-
tive regulator of the p53 tumor suppressor (MDM2) [41] 
and inflammation related factor (cyclooxygenase-2 and 
toll-like receptors) [31, 42]. Among the above-mentioned 
pathways or factors, it is interesting to note that in most 
studies, MAP4K4 exerts its function not through canoni-
cal MAPK pathways as expected. The nomenclature of 
Ste20 kinases as MAP4Ks was based on their regulation 
of MAPK pathways through activating MAP3Ks [2]. The 
first evidence of MAP4K4 regulation of MAPK/JNK came 
from a study showing that co-expression of kinase-defec-
tive MEKK1 and MAP4K4 in cultured adipocytes inhib-
ited the activation of JNK by MAP4K4 [8]. Consistent with 
this, a later study found that dominant-negative mutant 
of TAK1, an MAP3  K, significantly inhibited MAP4K4-
induced JNK activation [7]. Besides MAPK/JNK, MAP4K4 
has also been reported to regulate MAPK/ERK1/2 path-
way and MAPK/p38 pathway in biological systems other 
than cancer [43–46]. Together, current findings suggest 
that MAP4K4 may contribute to cancer mainly through 
canonical MAPK-independent mechanisms.
In addition to above mentioned candidate downstream 
mediators of MAP4K4, MAP4K4 also participated in the 
regulation of other cancer-related signaling pathways 
or factors including insulin pathway, hippo signaling 
(LATS1/2 and YAP/TAZ) and mTOR/AMPK [19, 21, 43, 
47–52]. Although experimental evidence that supports 
the link between MAP4K4 and these pathways and can-
cer is currently not available, it is reasonable to believe 
that MAP4K4 could contribute to cancer through modu-
lating these pathways or factors in a context-dependent 
manner.
How MAP4K4 regulates its downstream effectors or 
signaling mediators remains largely unexplored. Since 
MAP4K4 is a kinase, one would expect that the primary 
job of MAP4K4 is to phosphorylate its substrate. Indeed, 
MAP4K4 can directly phosphorylate TRAF2 at serine 35 
to promote its degradation in T cells [16]. However, none 
of these factors have been proved to be a direct phospho-
rylation substrate of MAP4K4 in cancer, implying that 
MAP4K4 regulates these factors or pathways indirectly. 
Identification of direct substrates of MAP4K4 will pro-
vide crucial clues as to how MAP4K4 is mechanistically 
involved in cancer.
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As summarized in Table  3, several MAP4K4-specific 
small-molecule inhibitors are currently available. Some 
of the inhibitors show promise in treating plaque devel-
opment, pathological angiogenesis in mice [12, 18, 53–
55]. Whether these inhibitors possess potent antitumor 
properties remains to be determined. Given the potential 
role of MAP4K4 in cancer, we believe MAP4K4 inhibi-
tion may be a possible new direction in cancer therapy.
Perspective
Current evidence supports but not yet provides sufficient 
biological and mechanistic justification for MAP4K4 as a 
novel cancer therapeutic target. Evidence definitely link-
ing MAP4K4 to the development and progression of any 
types of cancer is still lacking. To this end, it is essential to 
examine the impact of genetic manipulation of MAP4K4 
in mouse models of cancer. When interpreting results 
from experiments using MAP4K4 knockout mice (whole-
body or tissue-specific knockout), potential redundancy 
and functional compensation among MAP4Ks should be 
taken into consideration. Since small-molecule inhibitors 
of MAP4K4 are available, in order to eventually use these 
inhibitors in clinic, future studies should attempt to test 
their tumor prevention and antitumor activity in mouse 
models of cancer.
Currently there is no sufficient information suggesting 
in which type of cancer MAP4K4 inhibitor can be used 
as a novel promising therapy. Target overexpression is an 
overrated predictor of efficacy since it may also represent 
a cellular attempt to limit unbridled growth, unless func-
tional results from genetic manipulation of MAP4K4 in 
that particular tumor model are available, it is difficult 
to predict cancer types responsive to MAP4K4 inhibi-
tor treatment. It is possible that MAP4K4 could promote 
tumor development and progression in certain types of 
cancer and functions as a tumor repressor in other types 
of cancer, or plays different roles at different stages during 
tumor development and progression. Therefore it is cru-
cial to gain a thorough understanding of how MAP4K4 
is involved in a particular type of cancer functionally 
and mechanistically before conducting clinical testing of 
MAP4K4 inhibitor in cancer patients.
No information is available about whether and how 
MAP4K4 is involved in resistance to standard cancer 
therapy. If MAP4K4 contributes to cancer development 
and progression, it is highly likely that MAP4K4 can also 
be involved in treatment resistance. Therefore in addition 
to examine the potential anti-tumor activity of MAP4K4 
inhibitors as a standalone therapy, it is also important to 
test if MAP4K4 inhibitors can be used in combination to 
overcome resistance to chemotherapy, radiation therapy, 
targeted therapy and immunotherapy.
Detailed molecular understanding of how MAP4K4 is 
involved in cancer biology is essential for firmly estab-
lishing MAP4K4 as a target for that particular type of 
cancer. Crucial to this effort is to identify key upstream 
regulators and downstream effectors including substrates 
of MAP4K4. To develop efficient methods to block 
MAP4K4, it is also crucial to understand how MAP4K4 
functionally interacts with Ste20 family members.
Cancer remains a largely incurable disease, indicating 
an urgent and unmet need for novel effective therapeutic 
approaches. Identifying a novel cancer therapeutic tar-
get that could be amenable to pharmacologic interven-




































Fig. 2 Schematic diagram of suggested MAP4K4 downstream effec-
tors and biological outcomes in cancer. Studies on MAP4K4 in cancer 
have shown that MAP4K4 regulates different biological outcomes (red 
boxes) trough different cell signaling pathways (boxes with different 
colors), implicating that MAP4K4 exerts its role in regulation of tumori-
genesis and tumor progression in a biological context-dependent 
manner
Table 3 MAP4K4-specific small-molecule inhibitors
KI kinase inhibitor, NA not available
Name Type Specificity Biological/Preclinical disease model Clinical trial Ref.
GNE-495 KI MAP4K4 Angiogenesis in mouse model NA [12, 53]
GNE-220 KI MAP4K4 Angiogenesis in mouse model NA [12]
PF-6260933 KI MAP4K4 Vascular inflammation, atherosclerosis NA [18, 54]
4-Hydroxy-2-pyridone KI MAP4K4 Neuroblastoma cell NA [55]
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understanding of biological functions and underlying 
mechanisms of MAP4K4 in cancer could have far-reach-
ing implications for new directions in cancer therapy.
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